Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ADIL logo ADIL
Upturn stock ratingUpturn stock rating
ADIL logo

Adial Pharmaceuticals Inc (ADIL)

Upturn stock ratingUpturn stock rating
$0.68
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: ADIL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4Target price
Low$0.22
Current$0.68
high$1.37

Analysis of Past Performance

Type Stock
Historic Profit -73.41%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.29M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 3
Beta 1.19
52 Weeks Range 0.22 - 1.37
Updated Date 06/30/2025
52 Weeks Range 0.22 - 1.37
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.78

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -107.38%
Return on Equity (TTM) -217.01%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2401695
Price to Sales(TTM) -
Enterprise Value 2401695
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.49
Shares Outstanding 15775900
Shares Floating 7846338
Shares Outstanding 15775900
Shares Floating 7846338
Percent Insiders 3.41
Percent Institutions 3.64

Analyst Ratings

Rating 2
Target Price 4
Buy -
Strong Buy 2
Buy -
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Adial Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases of addiction. Founded in 2007, it aims to address unmet medical needs in the treatment of alcohol use disorder (AUD) and other addiction-related disorders. The company's lead product candidate is AD04, a genetically targeted therapeutic agent.

business area logo Core Business Areas

  • Therapeutic Development: Focuses on the research, development, and commercialization of AD04 for the treatment of Alcohol Use Disorder (AUD).
  • Genetic Testing: Incorporates a genetic test to identify patients most likely to respond to AD04, aiming for personalized treatment.

leadership logo Leadership and Structure

The company has a management team led by a CEO and includes individuals with expertise in clinical development, regulatory affairs, and commercialization. The organizational structure is typical of a small, clinical-stage biotech company, with departments focused on research, clinical trials, and business development.

Top Products and Market Share

overview logo Key Offerings

  • AD04: AD04 is Adial's lead product candidate, a genetically targeted therapeutic for Alcohol Use Disorder (AUD). It is currently in Phase 3 clinical trials. Since it is in development and not yet approved, there is currently no market share or revenue to report. Key competitors include pharmaceutical companies offering alternative treatments for AUD such as naltrexone (Vivitrol, Revia), acamprosate (Campral), and disulfiram (Antabuse).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry targeting addiction is driven by a significant unmet need for effective treatments. Alcohol Use Disorder (AUD) affects millions, creating a substantial market opportunity. The industry involves various players, from large pharmaceutical companies to smaller biotechs.

Positioning

Adial is positioned as a precision medicine company using a genetic approach to treat AUD. Its competitive advantage lies in its genetically targeted approach with AD04, aiming for higher efficacy and reduced side effects compared to traditional treatments.

Total Addressable Market (TAM)

The TAM for AUD treatments is substantial. Estimates range in the billions of dollars annually, globally. Adial aims to capture a portion of this market with AD04 through its unique genetically targeted approach, which the hope is will resonate within the medical community and patients suffering from AUD

Upturn SWOT Analysis

Strengths

  • Genetically targeted therapy (AD04)
  • Personalized medicine approach
  • Focus on unmet need in AUD treatment
  • Phase 3 clinical trial stage

Weaknesses

  • Reliance on a single product candidate (AD04)
  • Clinical trial risks and uncertainty
  • Limited financial resources
  • Small company size relative to competitors

Opportunities

  • Potential for FDA approval and commercialization of AD04
  • Expansion into other addiction-related disorders
  • Strategic partnerships with larger pharmaceutical companies
  • Positive clinical trial results enhancing investor confidence

Threats

  • Clinical trial failures
  • Regulatory hurdles and delays
  • Competition from existing AUD treatments
  • Market acceptance of genetically targeted therapies
  • Funding challenges and dilution

Competitors and Market Share

competitor logo Key Competitors

  • TEVA
  • VTRS
  • ALKS
  • OTCQX:SNOA

Competitive Landscape

Adial's genetically targeted approach differentiates it from competitors offering traditional pharmaceutical treatments. Its advantages lie in potentially higher efficacy and fewer side effects, but it faces challenges in terms of market acceptance and competition from established players.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by advancements in clinical trials and financing activities rather than revenue generation.

Future Projections: Future growth hinges on the successful completion of Phase 3 trials and potential FDA approval of AD04. Analyst projections vary, but positive results could lead to significant revenue growth.

Recent Initiatives: Recent initiatives include enrollment in the ONWARD Phase 3 clinical trial, and ongoing business development.

Summary

Adial Pharmaceuticals is a high-risk, high-reward clinical-stage company focused on a novel, genetically targeted approach to treating Alcohol Use Disorder. Its success is contingent upon the outcome of its ongoing Phase 3 clinical trials for AD04. The company's key strength is its innovative approach. It must carefully manage its financial resources and navigate the regulatory landscape to capitalize on the opportunities in the large and unmet market for AUD treatments. However, it remains vulnerable to clinical trial failures and competition from established treatments.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Adial Pharmaceuticals Inc. SEC Filings
  • Company Website
  • Analyst Reports

Disclaimers:

This analysis is based on available public information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Adial Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Glen Allen, VA, United States
IPO Launch date 2018-07-30
CEO, President & Director Mr. Cary John Claiborne MBA
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.